Licensing status

Publication and contact information


89Zr-transferrin agent for in vivo PET imaging of transferrin receptor protein 1 (TFRC; TFR; CD71)-expressing cancers

A 89Zr-transferrin PET imaging agent could help detect prostate and other cancers. The TFRC-binding agent consisted of 89Zr-labeled desferrioxamine (DFO) conjugated to human transferrin. In mice with TFRC-expressing xenografts or spontaneous prostate tumors, PET imaging of tumors with the 89Zr-transferrin agent provided higher signal-to-noise ratios than 18F-labeled fluorodeoxyglucose (FDG)-PET. In the spontaneous tumor model, PET imaging with 89Zr-transferrin detected high-grade prostate intraepithelial neoplasia (PIN), whereas 18F-FDG PET did not. Ongoing work includes IND-enabling studies of the agent to image undisclosed cancers (see Transferrin PET project, page 6).

SciBX 5(39); doi:10.1038/scibx.2012.1044
Published online Oct. 4, 2012

Unpatented; unlicensed

Holland, J.P. et al. Nat Med.; published online Sept. 23, 2012;
Contact: Jason S. Lewis, Memorial Sloan-Kettering Cancer Center, New York, N.Y.
Contact: Charles L. Sawyers, same affiliation as above